A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1,3-cyclohexanedione

Critical Reviews in Toxicology

Volumn 43, Issue 3, 2013, Pages 185-199

  Lewis, Richard W ^a   Botham, Jane W ^a  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

Author keywords

4 Hydroxyphenylpyruvate dioxygenase; Mouse; Rat; Risk assessment; Tyrosine

Indexed keywords

2 (4 METHYLSULFONYL 2 NITROBENZOYL) 1,3 CYCLOHEXANEDIONE; 4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; HERBICIDE; TYROSINE; TYROSINE AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CATABOLISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEALTH HAZARD; HUMAN; NONHUMAN; RAT; REVIEW; RISK ASSESSMENT;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ANIMALS; CYCLOHEXANONES; HERBICIDES; HUMANS;

EID: 84874503981     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2013.764279     Document Type: Review

References (28)

1. Burns RP, Gipson IK, Murray MJ. (1976). Keratopathy in tyrosinemia. Birth Defects, 12, 169-80.
2. Carmichael N, Bausen M, Boobis A, et al. (2011). Using mode of action information to improve regulatory decision making: an ECETOC/ILSR RF/HESI workshop overview. Crit Rev Toxicol, 41, 175-86.
3. D'Eufemia PD, Finocchiaro R, Celli M, et al. (2009). Increased nitric oxide release by neutrophils of a patients with tyrosinemia type III. Biomed Pharmacother, 63, 359-61.
4. Ellaway CJ, Holme E, Standing S, et al. (2001). Outcome of tyrosinaemia type III. J Inherit Metab Dis, 24, 824-32. (Pubitemid 34189394)
5. Ellis MK, Whitfield AC, Gowans LA, et al. (1995). Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoro-methylbenzoyl)- cyclohexane-1, 3-dione and 2-(2-chloro-4-methane-sulfonylbenzoyl)-cyclohexane-1, 3-dione. Toxicol Appl Pharmacol, 133, 12-9.
6. FDA. (2002) ORFADIN® capsules (nitisinone). Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2002/21-232-Orfadin.cfmf. [last accessed 15 Jan 2013].
7. Gledhill AJ, Jones BK, Laird WJD. (2001). Metabolism of 2-(4-methylsulphonyl 1-2-nitrobenzolyl)-1, 3-cyclohexanedione (meso-trione) in rat and mouse. Xenobiotica, 31, 733-47. (Pubitemid 33001097)
8. Hall MG, Wilks MF, Provan WM, et al. (2001). Pharmacokinetcs and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1, 3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol, 52, 169-77. (Pubitemid 32863075)
9. Henderson MJ, Faraj BT, Ali FM, Rudman D. (1981). Tyrosine transaminase activity in normal and cirrhotic liver. Dig Dis Sci, 26, 124-8. (Pubitemid 11184322)
10. Kretchmer N. (1959). Enzymic patterns during development. Paediatrics, 23, 606-17.
11. Lee DL, Prisbylla MP, Cromartie TH, et al. (1997). The discovery and structural requirements of inhibitors of p-hydroxyphenylpyruvate dioxygenase. Weed Sci, 45, 601-9. (Pubitemid 27414158)
12. Lindstedt S, Holme E, Lock EA, et al. (1992). Treatment of hereditart tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet, 340, 813-7.
13. Lock EA, Ellis MK, Provan WM, Smith LL. (1994). The effect of NTBC on enzymes involved in tyrosine catabolism in the rat. Toxicologist, 14, 826-32.
14. Lock EA, Gaskin P, Ellis MK, et al. (2000). Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1, 3-dione (NTBC) and its effects on enzymes involved in tyrosine catabolism in the mouse. Toxicology, 144, 179-87. (Pubitemid 30201635)
15. Lock EA, Gaskin P, Ellis MK, et al. (1996). Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexanedione (NTBC): effect on enzymes involved in tyrosine catabolism to ocular toxicity in the rat. Toxicol Appl Pharmacol, 141, 439-47. (Pubitemid 27046370)
16. Lock EA, Smith LS. (2003). The role of mode of action studies in extrapolating to human risks in toxicology. Toxicol Lett, 140-141, 317-22. (Pubitemid 36378951)
17. Meek ME, Bucher JR, Cohen SM, et al. (2003). A framework for human relevance analysis on information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591-654.
18. Nixon D. (2001). Mesotrione (ZA1296) tyrosine-mediated toxicity in mice and rats. Health Effects Division (HED) Mechanism of Toxicity science assessment Review Committee, 27 March 2001.
19. OECD Guidelines for Testing of Chemicals. (1998). Test Guideline 408. Repeat dose 90 day oral toxicity study in rodents.
20. OECD Guidelines for Testing of Chemicals. (2001). Test Guideline 416. Two generation reproduction study.
21. OECD Guidelines for Testing of Chemicals. (2001). Test Guideline 414. Prenatal developmental toxicity study.
22. OECD Guidelines for Testing of Chemicals. (2009). Test Guideline 453. Combined chronic toxicity/carcinogenicity study.
23. Rich LF, Beard ME, Burns RP. (1973). Excess dietary tyrosine and corneal lesions. Exp Eye Res, 17, 87-97.
24. Ruetschi U, Cerone R, Perez-Cerda C, et al. (2000). Mutations in the 4-hyroxyohenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum Genet, 106, 654-62. (Pubitemid 30427021)
25. Scott CR. (2006). The genetic tyrosinemias. Am J Med Genet C, 142C, 121-6.
26. Seed J, Carnet EW, Corley RA, et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol, 35, 663-72. (Pubitemid 41693589)
27. Sunwannarat P, O'Brien K, Perry MB, et al. (2005). Use of nitisinone in patients with alkaptonuria. Metabolism, 54, 719-28. (Pubitemid 40725319)
28. Yang C, Pflugrath JW, Camper DL, et al. (2004). Structural basis for herbicidal inhibitor selectivity revealed by comparison of crystal structures of plant and mammalian 4-hydroxyphenylpyruvate dioxy-genases. Biochemistry, 43, 10414-23. (Pubitemid 39079315)